patents.google.com

CN102002040A - Synthesis method of triazol pyridine ring compound - Google Patents

  • ️Wed Apr 06 2011

CN102002040A - Synthesis method of triazol pyridine ring compound - Google Patents

Synthesis method of triazol pyridine ring compound Download PDF

Info

Publication number
CN102002040A
CN102002040A CN2009100578595A CN200910057859A CN102002040A CN 102002040 A CN102002040 A CN 102002040A CN 2009100578595 A CN2009100578595 A CN 2009100578595A CN 200910057859 A CN200910057859 A CN 200910057859A CN 102002040 A CN102002040 A CN 102002040A Authority
CN
China
Prior art keywords
triazolopyridine
reaction
pyridine
synthetic method
cyclic cpds
Prior art date
2009-09-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009100578595A
Other languages
Chinese (zh)
Inventor
廖江鹏
林诗锐
陈贵红
肖贻崧
贺海鹰
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Apptec Co Ltd
Wuxi Apptec Tianjin Co Ltd
Original Assignee
Wuxi Apptec Co Ltd
Wuxi Apptec Tianjin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2009-09-01
Filing date
2009-09-01
Publication date
2011-04-06
2009-09-01 Application filed by Wuxi Apptec Co Ltd, Wuxi Apptec Tianjin Co Ltd filed Critical Wuxi Apptec Co Ltd
2009-09-01 Priority to CN2009100578595A priority Critical patent/CN102002040A/en
2011-04-06 Publication of CN102002040A publication Critical patent/CN102002040A/en
Status Pending legal-status Critical Current

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to a synthesis method of a triazol pyridine ring compound, which mainly solves the technical problems of low yield, high synthesizing cost, poor applicability and the like existing in the traditional synthesis method. The synthesis method comprises the following steps of: (1) making substituted 2-hydrazine-based pyridine react with substituted benzaldehyde, and (2) filtering sediments generated by reaction, dissolving the sediments in a solvent and adding lead tetraacetate, and refluxing to obtain a target product. The target product can be also obtained with a one-pot method by directly carry out the step (2) without separating the sediments. The synthesis method has the advantages of easy obtainment of simple raw materials, simple synthesizing steps, mild reaction condition and higher yield.

Description

A kind of synthetic method of Triazolopyridine cyclic cpds

Technical field:

The present invention relates to the synthetic method of the important potential drug molecule of class Triazolopyridine cyclic cpds.

Background technology:

Triazole compounds is the important drug molecule of a class, can be used for agricultural chemicals and make sterilant, plant-growth regulator.For example commercial paclobutrazol, triapenthenol etc. have very strong growth regulating effect to farm crop.Pharmaceutically have functions such as antibiotic, anti-inflammatory, spasmolytic, anti-platelet aggregation.The Triazolopyridine cyclic cpds has report as the important drug molecule of a class decades ago.

These reports mainly comprise two class synthetic methods:

1) reaction of the aroyl chloride of 2-hydrazino pyridine of Qu Daiing and replacement generates hydrazides, and refluxing in phosphorus oxychloride then generates the Triazolopyridine cyclic cpds.[J.D.Bower?and?F.P.Doyle,Journal?of?the?Chemical?Society,1957,727-732]

This method is used the highly toxic product phosphorus oxychloride in second step, operation danger, and yield is lower.

Its reaction formula is as follows:

Figure B2009100578595D0000011

2) reaction of 2-hydrazino pyridine and aromatic aldehyde generates the pyridine hydrazone, adds the diacetoxy iodobenzene then, and heating generates the Triazolopyridine cyclic cpds in solvent.[Sadana,Anil?K.;Mirza,Yasmin;Aneja,Kamal?R.;Prakash,Om;EuropeanJournal?of?Medicinal?Chemistry,2003,38,5,533-536]

Additive diacetoxy iodobenzene less stable in this method, price is higher, is unfavorable for the industry amplification.

Its reaction formula is as follows:

Figure B2009100578595D0000012

Summary of the invention:

The object of the present invention is to provide a kind of synthetic method of important drugs molecule Triazolopyridine cyclic cpds, mainly solve the low or difficult storage of starting material of existing synthetic method yield, use problems such as hypertoxic raw material and cost are too high.Technical scheme of the present invention: the synthetic method of Triazolopyridine cyclic cpds may further comprise the steps:

The first step: the 2-hydrazino pyridine 1 with replacement is a raw material, and with phenyl aldehyde 2 back flow reaction in organic solvent that replaces, the reaction solution cold filtration obtains white solid precipitation pyridine hydrazone class Schiff's base 3.

Second step: the pyridine hydrazone class Schiff's base 3 that filtration is obtained is dissolved in the organic solvent and adds lead tetra-acetate 4, and back flow reaction is after aftertreatment can obtain Triazolopyridine cyclic cpds 5.

This reaction also can obtain by one kettle way, i.e. the first step reaction is not come out precipitate and separate, directly carries out the operation of second step.Chemical equation is as follows:

R wherein 1Be selected from a kind of in trifluoromethyl, bromo or the nitro, R 2Be selected from hydrogen base, methyl, chloro or fluorine-based etc. in a kind of.

Above-mentioned synthetic method, organic solvent are selected from tetrahydrofuran (THF), N, a kind of in dinethylformamide, toluene or the ethanol, and the first step reflux time is 1-3 hour, the second step reflux time is 16-24 hour.

The invention has the beneficial effects as follows: the invention provides a kind of synthetic route of Triazolopyridine cyclic cpds, can prepare this class important drugs molecule quickly and easily from raw material cheap, that be easy to get.In the raw material, aromatic aldehyde is chemical goods, and the 2-hydrazino pyridine of replacement can be filtered by the 2-chloropyridine hydrazinolysis that replaces and obtain, reported in the past that the document of this compounds compared, the preparation that the present invention is not only successful target compound, and aftertreatment is also safer, easy to operate.

Embodiment: following example helps to understand content of the present invention, the present invention includes but is not limited to following related content:

Embodiment 1

Figure B2009100578595D0000022

Method one:

The synthesis technique of tolyl between 6-(trifluoromethyl)-3--[1,2,4] triazole [4,3-a] and pyridine:

In single neck bottle of 25 milliliters, add 5 milliliters of dehydrated alcohols, tolyl aldehyde (2,1.2 mmole), 0.177 gram 2-diazanyl-5-5-flumethiazine (1 between 0.144 gram, 1.0 mmole) heating reflux reaction is 2 hours, the TLC monitoring, aromatic aldehyde is cooled to room temperature after disappearing substantially.Filter out the white solid pyridine hydrazone Schiff's base that generates in the reaction.It is dissolved in 8 milliliters of dry toluenes, adds 1.2 mmole lead tetra-acetate, 80 ℃ of heated and stirred 18 hours.Be cooled to room temperature, add 5 ml waters, filter out the solid of separating out, and use acetic acid ethyl dissolution.The organic layer saturated sodium bicarbonate, the salt water washing, and use anhydrous sodium sulfate drying.Remove by filter sodium sulfate, revolve and desolvate, resistates separates (petrol ether/ethyl acetate=1: 1) with the preparation thin-layer chromatography and obtains tolyl between 6-(trifluoromethyl)-3--[1,2,4] triazole [4,3-a] and pyridine.

Method two:

The synthesis technique of tolyl between 6-(trifluoromethyl)-3--[1,2,4] triazole [4,3-a] and pyridine:

In single neck bottle of 25 milliliters, add 5 milliliters of dehydrated alcohols, tolyl aldehyde (2,1.2 mmole), 0.177 gram 2-diazanyl-5-5-flumethiazine (1,1.0 mmole) reflux between 0.144 gram, the TLC monitoring, aromatic aldehyde is cooled to room temperature after disappearing substantially.Add 1.2 mmole lead tetra-acetate, 80 ℃ of heated and stirred 18 hours.Be cooled to room temperature, add 5 ml waters, filter out the solid of separating out, and use acetic acid ethyl dissolution.The organic layer saturated sodium bicarbonate, the salt water washing, and use anhydrous sodium sulfate drying.Remove by filter sodium sulfate, revolve and desolvate, resistates separates (petrol ether/ethyl acetate=1: 1) with the preparation thin-layer chromatography and obtains tolyl between 6-(trifluoromethyl)-3--[1,2,4] triazole [4,3-a] and pyridine.Productive rate: 57%.

Fusing point is: 94 ℃.Proton nmr spectra 1HNMR (CDCl 3, 300MHz): δ 8.60 (d, J=1.2Hz, 1H), 7.96 (d, J=9.6Hz, 1H), 7.66-7.39 (m, 5H); Mass spectrum (ESI source): C 14H 10F 3N 3M/z 278 (M ++ 1).

According to method one or the method two of embodiment 1, we have also synthesized following Triazolopyridine compounds:

Embodiment 2

Figure B2009100578595D0000031

With p-tolyl aldehyde replace among the embodiment 1 between tolyl aldehyde obtain 6-(trifluoromethyl)-3-p-methylphenyl-[1,2,4] triazole [4,3-a] and pyridine, organic solvent is a tetrahydrofuran (THF), and the first step reflux time is 1 hour, and the second step reflux time is 16 hours.

Productive rate: 78%.Its fusing point: 108 ℃.Proton nmr spectra 1HNMR (CDCl 3, 300MHz):: δ 8.58 (d, J=1.2Hz, 1H), 7.95 (d, J=9.6Hz, 1H), 7.72 (dd, J=1.8Hz, 6.6Hz, 2H), 7.46-7.38 (m, 3H); Mass spectrum (ESI source): C 14H 10F 3N 3M/z 278 (M ++ 1).

Embodiment 3

Figure B2009100578595D0000041

With o-methyl-benzene formaldehyde replace among the embodiment 1 between tolyl aldehyde obtain 6-(trifluoromethyl)-3-o-tolyl-[1,2,4] triazole [4,3-a] and pyridine, organic solvent is an ethanol, and the first step reflux time is 1.5 hours, and the second step reflux time is 20 hours.

Productive rate: 77%.Its fusing point: 83 ℃.Proton nmr spectra 1HNMR (CDCl 3, 300MHz):: δ 8.16 (d, J=1.2Hz, 1H), 7.98 (d, J=9.6Hz, 1H), 7.56-7.40 (m, 5H); Mass spectrum (ESI source): C 14H 10F 3N 3M/z 278 (M ++ 1).

Embodiment 4

Figure B2009100578595D0000042

With phenyl aldehyde replace among the embodiment 1 between tolyl aldehyde obtain 6-(trifluoromethyl)-3-phenyl-[1,2,4] triazole [4,3-a] and pyridine, organic solvent is N, dinethylformamide, the first step reflux time is 3 hours, and the second step reflux time is 22 hours.

Productive rate: 88%.Proton nmr spectra 1HNMR (CDCl 3, 300MHz):: δ 8.62 (s, 1H), 7.98 (d, J=9.6Hz, 1H), 7.83-7.61 (m, 5H), 7.45 (d, J=9.6Hz, 1H); Mass spectrum (ESI source): C 13H 8F 3N 3M/z 264.0[M ++ 1]

Embodiment 5

Figure B2009100578595D0000043

With 4-chloro-benzaldehyde replace among the embodiment 1 between tolyl aldehyde obtain 6-(trifluoromethyl)-3-rubigan-[1,2,4] triazole [4,3-a] and pyridine.

Productive rate: 86%.Its fusing point: 120 ℃; Proton nmr spectra 1HNMR (CDCl 3, 300MHz):: δ 8.56 (d, J=1.2Hz, 1H), 7.98 (d, J=9.6Hz, 1H), 7.80-7.62 (m, 4H), 7.45 (dd, J=1.5Hz, 9.6Hz, 1H); Mass spectrum (ESI source): C 13H 7ClF 3N 3M/z 298[M ++ 1].

Embodiment 6

With p-Fluorobenzenecarboxaldehyde replace among the embodiment 1 between tolyl aldehyde obtain 6-(trifluoromethyl)-3-to fluorophenyl-[1,2,4] triazole [4,3-a] and pyridine.

Productive rate: 81%.Its fusing point: 117 ℃.Proton nmr spectra 1HNMR (CDCl 3, 300MHz):: δ 8.54 (d, J=1.2Hz, 1H), 7.98 (d, J=9.6Hz, 1H), 7.85-7.80 (m, 2H), 7.45 (dd, J=1.5Hz, 9.6Hz, 1H), 7.38-7.32 (m, 2H); Mass spectrum (ESI source): C 13H 7F 4N 3M/z 282.0[M ++ 1].

Embodiment 7

Figure B2009100578595D0000052

With adjacent fluorobenzaldehyde replace among the embodiment 1 between tolyl aldehyde, replace the 2-diazanyl-5-5-flumethiazine among the embodiment 1 to obtain 6-bromo-3-neighbour fluorophenyl-[1,2,4] triazole [4,3-a] and pyridine with 2-diazanyl-5-bromopyridine.

Productive rate: 95%.Proton nmr spectra 1HNMR (CDCl 3, 400MHz):: δ 8.03 (t, J=1.2Hz, 1H), 7.79-7.69 (m, 2H), 7.57-7.52 (m, 1H), 7.36-7.24 (m, 3H); Mass spectrum (ESI source): C 12H 7BrFN 3M/z 291[M ++ 1].

Embodiment 8

Figure B2009100578595D0000053

With adjacent fluorobenzaldehyde replace among the embodiment 1 between tolyl aldehyde, replace the 2-diazanyl-5-5-flumethiazine among the embodiment 1 to obtain 8-bromo-3-neighbour fluorophenyl-[1,2,4] triazole [4,3-a] and pyridine with 2-diazanyl-3-bromopyridine.

Productive rate: 100%.Proton nmr spectra 1HNMR (CDCl 3, 400MHz): δ 7.88-7.76 (m, 2H), 7.56-7.50 (m, 2H), 7.34-7.19 (m, 2H), 6.74 (t, J=6.8Hz, 1H); Mass spectrum (ESI source): C 12H 7BrFN 3M/z 291[M ++ 1].

Embodiment 9

With adjacent fluorobenzaldehyde replace among the embodiment 1 between tolyl aldehyde, replace the 2-diazanyl-5-5-flumethiazine among the embodiment 1 to obtain 7-nitro-3-neighbour fluorophenyl-[1,2,4] triazole [4,3-a] and pyridine with 2-diazanyl-4-nitropyridine.

Productive rate: 89%.Proton nmr spectra 1HNMR (CDCl 3, 400MHz): δ 8.76 (d, J=1.6Hz, 1H), 8.04-8.01 (dd, J=3.6,7.6Hz, 1H), 7.86-7.82 (m, 1H), 7.65-7.57 (m, 2H), 7.40-7.32 (m, 2H); Mass spectrum (ESI source): C 12H 7FN 4O 2M/z 259[M ++ 1].

Claims (5)

1. the synthetic method of a Triazolopyridine cyclic cpds is characterized in that may further comprise the steps:

The first step: the 2-hydrazino pyridine 1 with replacement is a raw material, and with phenyl aldehyde 2 back flow reaction in organic solvent that replaces, the reaction solution cold filtration obtains white solid precipitation pyridine hydrazone class Schiff's base 3.

Second step: the pyridine hydrazone class Schiff's base 3 that filtration is obtained is dissolved in the organic solvent and adds lead tetra-acetate 4, and back flow reaction is after aftertreatment can obtain Triazolopyridine cyclic cpds 5;

Reaction formula is as follows:

Figure F2009100578595C0000011

R wherein 1Be selected from a kind of in trifluoromethyl, bromo or the nitro, R 2Be selected from hydrogen base, methyl, chloro or fluorine-based in a kind of.

2. the synthetic method of a kind of Triazolopyridine cyclic cpds according to claim 1 is characterized in that adopting the one kettle way reaction, i.e. the first step reaction is not come out precipitate and separate, directly carries out the reaction of second step.

3. the synthetic method of a kind of Triazolopyridine cyclic cpds according to claim 1 and 2 is characterized in that, described organic solvent is selected from tetrahydrofuran (THF), N, a kind of in dinethylformamide, toluene or the ethanol.

4. the synthetic method of a kind of Triazolopyridine cyclic cpds according to claim 1 and 2 is characterized in that the first step reflux time is 1-3 hour.

5. the synthetic method of a kind of Triazolopyridine cyclic cpds according to claim 1 and 2 is characterized in that, the second step reflux time is 16~24 hours.

CN2009100578595A 2009-09-01 2009-09-01 Synthesis method of triazol pyridine ring compound Pending CN102002040A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009100578595A CN102002040A (en) 2009-09-01 2009-09-01 Synthesis method of triazol pyridine ring compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009100578595A CN102002040A (en) 2009-09-01 2009-09-01 Synthesis method of triazol pyridine ring compound

Publications (1)

Publication Number Publication Date
CN102002040A true CN102002040A (en) 2011-04-06

Family

ID=43809773

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009100578595A Pending CN102002040A (en) 2009-09-01 2009-09-01 Synthesis method of triazol pyridine ring compound

Country Status (1)

Country Link
CN (1) CN102002040A (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8299101B2 (en) 2007-03-07 2012-10-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators
US8399493B2 (en) 2004-09-17 2013-03-19 Janssen Pharmaceuticals, Inc. Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8716480B2 (en) 2009-05-12 2014-05-06 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9708315B2 (en) 2013-09-06 2017-07-18 Janssen Pharmaceutica Nv 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
US10106542B2 (en) 2013-06-04 2018-10-23 Janssen Pharmaceutica Nv Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11369606B2 (en) 2014-01-21 2022-06-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399493B2 (en) 2004-09-17 2013-03-19 Janssen Pharmaceuticals, Inc. Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US9266834B2 (en) 2006-03-15 2016-02-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8299101B2 (en) 2007-03-07 2012-10-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators
US9067891B2 (en) 2007-03-07 2015-06-30 Janssen Pharmaceuticals, Inc. 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8748621B2 (en) 2007-09-14 2014-06-10 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US11071729B2 (en) 2007-09-14 2021-07-27 Addex Pharmaceuticals S.A. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US9132122B2 (en) 2007-09-14 2015-09-15 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US10071095B2 (en) 2009-05-12 2018-09-11 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
US8716480B2 (en) 2009-05-12 2014-05-06 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9226930B2 (en) 2009-05-12 2016-01-05 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US9737533B2 (en) 2009-05-12 2017-08-22 Janssen Pharmaceuticals. Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US10106542B2 (en) 2013-06-04 2018-10-23 Janssen Pharmaceutica Nv Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US10584129B2 (en) 2013-06-04 2020-03-10 Janssen Pharmaceuticals Nv Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
US9708315B2 (en) 2013-09-06 2017-07-18 Janssen Pharmaceutica Nv 1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11103506B2 (en) 2014-01-21 2021-08-31 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US11369606B2 (en) 2014-01-21 2022-06-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US12048696B2 (en) 2014-01-21 2024-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Similar Documents

Publication Publication Date Title
CN102002040A (en) 2011-04-06 Synthesis method of triazol pyridine ring compound
Basavaiah et al. 2002 Applications of Baylis–Hillman chemistry: one-pot convenient synthesis of functionalized (1H)-quinol-2-ones and quinolines
CN113292535B (en) 2022-07-01 Method for preparing apaluamide intermediate and apaluamide
CN108047198B (en) 2020-06-02 Method for preparing polyaryl substituted naphthalene derivative by reaction of aryl ketone and tolane under catalysis of ruthenium
KR101345394B1 (en) 2013-12-24 Process for preparing 5-(3,6-dihydro-2,6-dioxo-4-trifluoromethyl-1(2h)-pyrimidinyl)phenylthiol compounds
WO2006021974A1 (en) 2006-03-02 A process for synthesizing diol (viii)-an intermediate of montelukast sodium
CN105330598A (en) 2016-02-17 Preparing method for pirfenidone
WO2010122794A1 (en) 2010-10-28 Process for production of pyrazinecarboxylic acid derivative, and intermediate for the production
CN107235967A (en) 2017-10-10 The synthesis technique of antineoplastic Tegafur
CN105949118A (en) 2016-09-21 Preparation method of 2-aryl quinoline derivatives
NZ582589A (en) 2012-03-30 Process for producing toluidine compound fluazinam
CN105153013B (en) 2017-12-29 The synthetic method of the ketone of 6 bromine isoindoline 1
CN100497309C (en) 2009-06-10 Method for synthesizing heteroaryl thiosemicarbazone antineoplastic
CN106957237A (en) 2017-07-18 A kind of method for synthesizing bromfenac sodium
CN100408577C (en) 2008-08-06 Process for the preparation of imidazo (1, 2-A) pyridine-3-acetamides
CN105130886A (en) 2015-12-09 Preparation method for 4-fluoro-3-methyl-methyl pyridine-2-carboxylate
CN105968108B (en) 2017-07-04 A kind of method for synthesizing Pabuk former times profit cloth intermediate
CN103086962A (en) 2013-05-08 Synthetic method for 5-chlorine-2,4-dyhydroxyl pyridine
CN101270071A (en) 2008-09-24 A method for synthesizing 1-alkyl-2-alkoxy-3-indole aldoxime derivatives
US9611217B2 (en) 2017-04-04 Synthetic processes of carprofen
JP2015038052A (en) 2015-02-26 Bisaminoimine ligand having binaphthol skeleton and catalyst
CN104177284B (en) 2016-08-24 The method of synthesis 3-azabicyclic [3,1,0] hexyl-1-formaldehyde
JPH061776A (en) 1994-01-11 Production of substituted pyrazinecarbonitrile
CN103044313A (en) 2013-04-17 Method for synthesising carbazole compounds
CN102320957A (en) 2012-01-18 Method for preparing 4-(2,4,5-trifluorophenyl)-3-oxo-butanoic acid

Legal Events

Date Code Title Description
2011-04-06 C06 Publication
2011-04-06 PB01 Publication
2013-05-08 C02 Deemed withdrawal of patent application after publication (patent law 2001)
2013-05-08 WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110406